Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2015 · 10-K
Revenue$6.22M$6.22M−57.5% vs Q4 2014 Net Income-$40.62M-$40.62MderivedN/M vs Q4 2014 EPS Diluted-$1.08-$1.08N/M vs Q4 2014 Operating Income-$40,897,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
N/M
Operating Cash Flowderived-$30,529,000N/M Free Cash Flowderived-$32,715,000N/M Margins · derivedOperating margin-657.7%−475.1 pt vs Q4 2014
Net margin-653.3%−471.1 pt vs Q4 2014
ended Dec 31, 2015 · filed Feb 26, 2016 · 57 d after period end